Glenn Verstraete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Glenn Verstraete has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Chris Vervaet
Laboratory of Pharmaceutical Technology, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
8 shared publications J.P. Remon
Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
8 shared publicationsT. De Beer
Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ghent, Belgium
7 shared publications- Valérie Vanhoorne
Laboratory of Pharmaceutical Technology, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg, 460, 9000 Ghent, Belgium
5 shared publications - W. Grymonpré
Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
5 shared publications J. Van Renterghem
Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ghent, Belgium
3 shared publications
Latest Publications
- 1 April 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 541 (1-2) , 108-116
The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets
- 1 April 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 541 (1-2) , 108-116
The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets
- 1 January 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 536 (1) , 318-325
3D printing of high drug loaded dosage forms using thermoplastic polyurethanes
- 1 January 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 536 (1) , 318-325
3D printing of high drug loaded dosage forms using thermoplastic polyurethanes
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 531 (1) , 235-245
Downstream processing from hot-melt extrusion towards tablets: A quality by design approach
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 531 (1) , 235-245
Downstream processing from hot-melt extrusion towards tablets: A quality by design approach
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 218-226
Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 218-226
Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis
- Open Access
- 1 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0172723
Evaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models
Burkholderia cenocepacia is an opportunistic pathogen responsible for life-threatening infections in cystic fibrosis patients. B. cenocepacia is extremely resistant towards antibiotics and therapy is complicated by its ability to form biofilms. We investigated the efficacy of an alternative antimicrobial strategy for B. cenocepacia lung infections using in vitro and in vivo models. A screening of the NIH Clinical Collection 1&2 was performed against B. cenocepacia biofilms formed in 96-well microtiter plates in the presence of tobramycin to identify repurposing candidates with potentiator activity. The efficacy of selected hits was evaluated in a three-dimensional (3D) organotypic human lung epithelial cell culture model. The in vivo effect was evaluated in the invertebrate Galleria mellonella and in a murine B. cenocepacia lung infection model. The screening resulted in 60 hits that potentiated the activity of tobramycin against B. cenocepacia biofilms, including four imidazoles of which econazole and miconazole were selected for further investigation. However, a potentiator effect was not observed in the 3D organotypic human lung epithelial cell culture model. Combination treatment was also not able to increase survival of infected G. mellonella. Also in mice, there was no added value for the combination treatment. Although potentiators of tobramycin with activity against biofilms of B. cenocepacia were identified in a repurposing screen, the in vitro activity could not be confirmed nor in a more sophisticated in vitro model, neither in vivo. This stresses the importance of validating hits resulting from in vitro studies in physiologically relevant model systems.
- 1 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0172723
Open AccessEvaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models
Burkholderia cenocepacia is an opportunistic pathogen responsible for life-threatening infections in cystic fibrosis patients. B. cenocepacia is extremely resistant towards antibiotics and therapy is complicated by its ability to form biofilms. We investigated the efficacy of an alternative antimicrobial strategy for B. cenocepacia lung infections using in vitro and in vivo models. A screening of the NIH Clinical Collection 1&2 was performed against B. cenocepacia biofilms formed in 96-well microtiter plates in the presence of tobramycin to identify repurposing candidates with potentiator activity. The efficacy of selected hits was evaluated in a three-dimensional (3D) organotypic human lung epithelial cell culture model. The in vivo effect was evaluated in the invertebrate Galleria mellonella and in a murine B. cenocepacia lung infection model. The screening resulted in 60 hits that potentiated the activity of tobramycin against B. cenocepacia biofilms, including four imidazoles of which econazole and miconazole were selected for further investigation. However, a potentiator effect was not observed in the 3D organotypic human lung epithelial cell culture model. Combination treatment was also not able to increase survival of infected G. mellonella. Also in mice, there was no added value for the combination treatment. Although potentiators of tobramycin with activity against biofilms of B. cenocepacia were identified in a repurposing screen, the in vitro activity could not be confirmed nor in a more sophisticated in vitro model, neither in vivo. This stresses the importance of validating hits resulting from in vitro studies in physiologically relevant model systems.
- 1 January 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 517 (1-2) , 348-358
In-line monitoring of compaction properties on a rotary tablet press during tablet manufacturing of hot-melt extruded amorphous solid dispersions
- 1 January 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 517 (1-2) , 348-358
In-line monitoring of compaction properties on a rotary tablet press during tablet manufacturing of hot-melt extruded amorphous solid dispersions
- 1 November 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 513 (1-2) , 602-611
A comparative study between melt granulation/compression and hot melt extrusion/injection molding for the manufacturing of oral sustained release thermoplastic polyurethane matrices
- 1 November 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 513 (1-2) , 602-611
A comparative study between melt granulation/compression and hot melt extrusion/injection molding for the manufacturing of oral sustained release thermoplastic polyurethane matrices
- Open Access
- 5 July 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (29) , 8098-8103
pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Significance: The newest generation of small-molecule vaccine adjuvants aims at triggering specific receptors expressed by dendritic cells, the working horses of our immune system. Unfortunately, owing to their small size, upon administration these molecules rapidly enter systemic circulation and cause systemic inflammation. We report on a nanotechnology-based solution for this issue by covalent ligation of a potent immunostimulatory small molecule to hydrogel nanoparticles. This approach allows for lymph node-restricted immune activation and avoids systemic dissemination. Importantly, relative to soluble immunostimulatory compound, nanoparticle ligation yields increased immune activation in the draining lymph nodes and results in strongly increased antibody titers and T-cell responses against an admixed vaccine antigen.
- 5 July 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (29) , 8098-8103
Open AccesspH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Significance: The newest generation of small-molecule vaccine adjuvants aims at triggering specific receptors expressed by dendritic cells, the working horses of our immune system. Unfortunately, owing to their small size, upon administration these molecules rapidly enter systemic circulation and cause systemic inflammation. We report on a nanotechnology-based solution for this issue by covalent ligation of a potent immunostimulatory small molecule to hydrogel nanoparticles. This approach allows for lymph node-restricted immune activation and avoids systemic dissemination. Importantly, relative to soluble immunostimulatory compound, nanoparticle ligation yields increased immune activation in the draining lymph nodes and results in strongly increased antibody titers and T-cell responses against an admixed vaccine antigen.